InspireMD Business Summary

InspireMD, Inc. (NSPR) is a commercial-stage medical device company specializing in carotid artery disease treatment and stroke prevention through its proprietary MicroNet mesh technology. The company generates revenue primarily through the sale of its CGuard Embolic Prevention System (EPS) and the next-generation CGuard Prime, which received FDA Premarket Approval (PMA) in June 2025. Its business model has transitioned toward a direct sales approach in the United States following its 2025 commercial launch, while maintaining a network of international distribution partners across Europe, Latin America, and Asia. The product portfolio is anchored by the CGuard Prime stent and the SwitchGuard neuroprotection system, designed for transcarotid artery revascularization (TCAR). InspireMD competes directly with Silk Road Medical, Boston Scientific, Edwards Lifesciences, and KORU Medical Systems, positioning itself as a superior technological alternative to traditional carotid endarterectomy by offering the industry's lowest reported major adverse event rates through its dual-layer mesh design. Leadership is led by President and CEO Marvin Slosman, a 30-year medtech veteran with an MBA from the University of Chicago and prior executive roles at GE Healthcare, Baxter, and ITAMAR Medical. The financial strategy is overseen by CFO Michael Lawless, appointed in June 2025, who brings over two decades of experience from Lifeward (formerly ReWalk Robotics) and Brooks Automation, holding an MBA from Dartmouth’s Tuck School of Business. The executive team is supported by CCO Shane Gleason and COO Andrea Tommasoli, both possessing extensive cardiovascular device pedigrees. The company’s Board of Directors features high-profile industry figures, including Chairman Paul Stuka, carotid stenting pioneer Dr. Gary Roubin, and former Boston Scientific/Scimed President Michael Berman. Notable institutional backing includes significant positions from OrbiMed, Marshall Wace, and Soleus Capital, following a major $113.6 million private placement to fund the company's U.S. commercial expansion.